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COMMENT
VIABILITY OF A NATIONWIDE FEN-PHEN/REDux CLASS
ACTION LAWSUIT IN LIGHT OFAMCHEM V. WINDSOR
I. INTRODUCTION
In 1995, Linda Rhoades was first introduced to the "miracle" drug com-
bination known as fen-phen. Her doctor prescribed the popular diet drug
combination of fenfluramine and phentermine, better known as "fen-phen,"
so she could lose weight After successfully losing some weight, Linda went
to see her doctor for a routine examination. Unfortunately for Linda, the ex-
amination revealed that Linda's heart valve was severely damaged Sadly,
Linda's heart valve was so severely damaged that she inevitably needed
open-heart surgery to replace her damaged valve.
Last year, Linda had her heart valve replaced; however, this did not
solve Linda's heart problems. Linda's recovery from heart valve surgery was
complicated due to a second damaged heart valve.' Although her symptoms
from the second damaged valve are controlled with medication, the second
valve will likely have to be replaced some time in the future. For Linda, that
means frequent visits to her cardiologist and the constant fear of not know-
ing what lies in her future. Linda stated, "it's pretty disconcerting... I don't
know if I have the normal life expectancy that I would have had... I'm kind
of playing a waiting game to see what's gonna happen."
While heart valve damage is not a wholly new phenomenon, what is
new is the cause of her damaged heart valves, fen-phen. After Linda
Rhoades's doctor first discovered valve damage, Linda was referred to the
Mayo Clinic in Rochester, Minnesota, where Dr. Heidi Connolly treated her.
Dr. Connolly was the first doctor in the United States to make the connection
between the use of fen-phen and heart valve damage! Then in July 1997, the
Mayo clinic released a study showing that twenty-four people, including
Linda, with no prior heart conditions had developed heart valve damage after
taking fen-phen.6 These initial findings by the Mayo Clinic eventually led
1. See CBS This Morning: Analysis: Long-term Health Problems Caused by Obesity
Drugs (CBS television broadcast, Feb. 24, 1998).
2. See id
3. See id
4. Id
5. See id
6. See Paul D. Rheingold, Fen-Phen/Redux Diet Drugs, MEALEY'S LrrIG. Rpr.: DRuG &
1
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the FDA to request that the "fen" part of fen-phen and dexfenfluramine, also
known as Redux or Pondimin (which is chemically similar to fen) be re-
moved from the market
Unfortunately, it seems that fen-phen was not removed from market
shelves soon enough. It has been reported that approximately six million
Americans took the diet drugs and of that number, approximately twenty-
five to thirty-three percent of those persons will develop serious physical
conditions.8
With so many millions of people exposed to these diet pills, the inevita-
ble questions remain as to who is to blame and who is going to pay for all
the damage. While the allegations of who is to blame are still long from be-
MEDICAL DEVICes, Aug. 1, 1997, at 22. In July 1996, a report from the Mayo Clinic was re-
leased stating that they had seen some 24 patients (all women) who had developed heart valve
damage while on fen-phen. See id This was perhaps the most startling bad news about the
diet drugs, and indeed provided the catalyst for the current attention to litigation.
In the report, Dr. Heidi Connolly and others at Mayo and at a clinic in Fargo, North Dakota,
reported 24 women with no previous heart or lung disease who were on fen-phen for a mean
duration of 12 months, had developed very unusual and specific heart valve damage. See id
This lead to surgical replacement of at least five valves. See id
7. See id. In late 1996, the FDA requested that Wyerth-Ayerst issue a "dear doctor" letter
regarding fenfluramine. See id The letter cautioned physicians about Primary Pulmonary Hy-
pertension as a possible side effect. See id The letter stated that fenfluramine should only be
used by persons whose Body Mass Index is 30 or more and not for "cosmetic" weight loss.
See id (for a discussion of Body Mass Index, see infra Part II.B). It also stated that neither the
FDA nor Wyeth approved the combined use of fenfluramine and phentermine. See id How-
ever, it did not advise doctors not to prescribe the combination, and obviously the seller of
fenfluramine obtains benefits from the combination sale. See id
On July 8, 1997, after the Mayo study was released, the FDA issued a Public Health Advisory
about heart valve disease. See id The FDA reported it was aware of 33 such cases and was
obviously describing the Mayo study. See id It sought reports from physicians on fen-phen
and Redux to its MEDWATCH program. See id MEDWATCH is the FDA medical reporting
program that requires manufacturers, packers and distributors to report to the FDA adverse
affects of new drugs. See New Drugs, 21 C.F.R. § 310.305 (1998). The FDA advisory re-
minded all doctors that the safety and effectiveness of fen-phen has not been established and
that "serious concerns about the safety of such combined use have been raised." Rheingold,
supra note 6, at 22. If doctors were to prescribe it, the FDA recommended that doctors "fol-
low patients closely with thorough cardiac evaluations, and if signs and symptoms of cardio-
pulmonary disease developed further cardiac evaluation should be pursued." Id.
The future of Pondimin and Redux was destroyed in early September, when the FDA received
the results of echocardiograph studies (an echocardiograph is the record produced from an
ultrasound of the heart that displays an image of the heart valves indicating the extent of dam-
age) conducted on patients who had used the drugs. See id Even though the number of sub-
jects was just 284 among five studies, the results were alarming: Nearly one in three had evi-
dence of heart valve disease. See id Under pressure from the FDA, American Home Products
and Interneuron, manufacuturers of the diet drugs, recalled Pondimin and Redux. See id Al-
though an AHP spokesperson refused to confirm the figure, "it's been reported that the recall
cost the company between $200 million and $300 million.' Bob Van Voris, Fen-Phen Suits
Grow: Panel Mulls MDL Forum For Diet-Drug Litigation as Feds Urge Heart Exams, NAT'L
L.J., Dec. 1, 1997, at Al.
8. See Jacqueline Soteropoulos, Attorneys Court Diet-Drug Clients, TAMPA TRIBUNE,
Dec. 8, 1997, at 1. The potential plaintiff class is about three or four times the number of
women who received breast implants, which sparked a tremendous wave of lawsuits. See id
2
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ing resolved, one thing that is certain is how they are going to find out - liti-
gation. Within the framework of litigation, plaintiffs' lawyers are hotly con-
testing the merits of pursuing class action lawsuits versus individual law-
suits!
Aside from strategic considerations, lawyers are also faced with the Su-
preme Court's July 1997 decision in Amchem v. Windsor Products"0 making
the requirements for class action certification more stringent. This Comment
will explore the legal implications of the Amchem decision using the fen-
phen/Redux scenario as a model. Part I of this Comment will discuss the
evolution and medical implications of the fen-phen/Redux predicament. Part
II will focus on the Amchem decision and its effects on recent lawsuits
seeking class action certification. Part IlI will discuss the various approaches
to resolving the fen-phen/Redux litigation as well as the likelihood of suc-
cessful class certification.
II. THE EVOLUTION AND MEDICAL IMPLICATIONS OF THE FEN-PHEN/REDUX
PREDICAMENT
A. The Introduction of the Drug Combination Fen-Phen and FDA Approval
of Redux
The drugs comprising the fen-phen combination have been around for
years. Phentermine ("phen') was approved by the U.S. Food and Drug Ad-
ministration (FDA) in 1959 and fenfluramine ("fen") in 1973, both for short-
term weight loss treatment." But it was not until 1992 that a study sponsored
by the National Institute of Health suggested that patients could achieve
dramatic weight loss by taking the drugs in combination."
The FDA never approved the combined use of these two drugs.'3
"Hence the physician who prescribed a fen-phen regimen made an off-label
use of a prescription drug."'4 Although physicians may prescribe drugs in a
manner that does not comport with FDA indications, there are inherent risks
9. See Mark Hansen, Fen-Phenomenal Tort Battle Brewing, 84 A.B.A. J. 24 (1998).
10. 117S. Ct. 2231,2243 (1997).
11. See Van Voris, supra note 7, at Al.
12. See id Fenfluramine is sold under the trade name Pondiniin (also "Ponderol"), by
A.H. Robins, which is a subsidiary of American Home Products, Inc. Phentermine is sold un-
der a number of trade names including Ionamin (Medeva); Fastin (Smithkline Beecham);
Adipex (Gate); Banobese (Seatrace); Obenix (Abana Pharmaceuticals); Obycap (Richwood);
Zantryl (Ion). See Rheingold, supra note 6, at 22.
13. See Rheingold, supra note 6, at 22. "Fenfluramine increases the amount of available
serotonin (a neurotransmitter), by inhibiting its reuptake. Increased level of serotonin gives
the brain the sign of satiety. Phentermine works on dopamine, another neurotransmitter (in the
catecholamine system). The increase of serotonin is directly related to the serious side ef-
fects." I&L
14. Id
3
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of such practices.15
The FDA approved Redux in April 1996, in the middle of the 1996 fen-
phen prescription boom. 6 Chemically, Redux is similar to fenfluramine, but
it was intended for long-term use." The understanding was that a person
must continue to take it in order to maintain the weight loss.
Even though Redux had received FDA approval, unlike the combined
use of fen-phen, the process by which Redux received FDA approval is sus-
pect. Marianne Ewalenko, a cardiologist in Belgium, discovered leaky heart
valves in seven of her patients, and found that each of them had taken diet
pills." Dr. Ewalenko informed the French manufacturer and gave several
talks at obesity conferences on or detailing the unusual link between leaky
heart valves and diet pills." While this may not seem significant considering
the number of people that have reported heart valve problems, Dr.
Ewalenko's discovery was in 1994. It was, in other words, more than three
and a half years before the same diet pills, fen-phen, were pulled from the
United States market."
As part of the FDA approval process, U.S. pharmaceutical companies
are required to notify the FDA quickly of any "serious and unexpected" ad-
verse effects in users of drugs they market. They must notify the FDA re-
gardless of whether the effects occur in the United States or abroad, and
whether or not they appear to be related to the drug.' American Home Prod-
ucts (AHP) stated after the Mayo study was released that they had known of
the twenty-five Belgian cases and six others elsewhere in Europe.' AHP said
it told the FDA of ten of the cases and the FDA confirms receiving eight2 6
AHP decided not to report all of the patients that had developed heart
valve damage because they felt the unreported cases did not fit within the
reporting requirements of the FDA?2 Hence, it will be left to the litigation
15. See Rheingold, supra note 6, at 22.
16. See Kathleen Kerr, FDA Sued Over Diet Drug Study/Watchdog Group Investigates
"fen-phen' Safety, NEwSDAY, Jan. 15, 1998, at A22. "Questions about the safety of Redux
emerged in 1995 when an FDA advisory group voted not to recommend the pill for market
because of concerns that it might cause brain damage in humans. But FDA officials decided
to discard the advisory group's recommendation and called for another vote. In a second 6-5
vote, the group recommended that the FDA approve Redux for market." Id.
17, See Van Voris, supra note 7, at Al.
18. See Rheingold, supra note 6, at 22.
19, See Laura Johannes & Steve Stecklow, Early Warning: Heart-Valve Problem That
FelledDiet Pills HadArisen Previously, WALL ST. J., Dec. 11, 1997, at Al.
20. See id,
21. See id
22. See id
23. New Drugs, 21 C.F.R. §310.305 (1998).
24. See id.
25. See Johannes & Stecklow, supra note 19, at Al.
26. See id
27. See id. "We reported everything that we thought was 'serious and unexpected,"' says
Joseph Pittelli, executive vice president of research at the company's Wyeth-Ayerst Laborato-
202 [Vol. 35
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process to find out what exactly AHP and Interneuron knew, when they
knew it, and whether they should have reported it.
B. The Intended Use of Fen-Phen and the Reality of Use Differed Drastically
Redux was approved by the FDA only on the further condition that it be
prescribed exclusively for obesity, defined as a BMI (body mass index) of
thirty kiligrams per square meter or greater.28 Moreover, it was to be pre-
scribed only in conjunction with an overall regimen relating to weight loss,
including active dieting and exercise. 9 Thus, at least as conceived by the
FDA, it was a drug with some risk to be used for a serious health condition
and given under controlled conditions to people who are diagnosed as obese
by medical specialists."
Although the purpose may have been to prescribe fen-phen and Redux
for clinically-obese persons, the reality was something quite different. Prior
to being pulled from the United States market, the prescribing of both fen-
phen and Redux seem to have gotten "wholly out of hand."31 Miracle weight
loss ads for fen-phen appeared everywhere. Redux was prescribed for the
loss of a few pounds to persons who were not obese to begin with?3 Sales-
persons for Redux visited every type of doctor.4 The Wall Street Journal re-
ported that there were eighteen million prescriptions written in one month
for fen-phen in 1996." It was reported that fen-phen was given away for free
if persons signed up at diet centers such as Nutri-System 6 Other reports
stated a prescription could be obtained over the internet by simply using
ries. Id. "American Home's reason for not telling the FDA about the six European cases out-
side Belgium is that those pill takers' main problem was a lung disorder already known to be
a possible side effect." Id As for the 15 Belgian cases it did not report, the company ex-
plained that it did not consider them to be serious and unexpected because some of the Bel-
gian patients were also taking Chinese herbs to lose weight, herbs suspected of leading to an-
other dangerous condition, kidney disease. See id. See also New Drugs, C.F.R. § 310.305
(1998) (defining adverse drug experiences that need to be reported).
28. See Rheingold, supra note 6, at 22. Fen-phen was never assigned a BMI number by
the FDA since the FDA never approved the combined use of the drugs. However, it will likely
be argued by plaintiffs' lawyers that fen-phen, like Redux, should have only been prescribed
for obese persons whose BMI number was greater than 30. See id
29. See id
30. See id. Redux, sold by Wyeth-Ayerst Laboratories, is also a subsidiary of American
Home Products. See id. "The generic name for this product is dexfenfluramine, a purified
form of fenfluramine. Fenfluramine is racemic, meaning that it has both levo and dextro iso-
mers, although only the 'dextro' half is pharmaceutically active. Dexfenfluramine is just the
active half of fenfluramine and the idea is that the toxicity of fenfluramine might be reduced if
some side effects are being caused by the levo part." Id.
31. Rheingold, supra note 6, at 22.
32. See id
33. See id
34. See id
35. See id
36. See id
5
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their credit card. 7 'This conjures up pictures of a person in one state taking a
faxed prescription into a drug store, signed by a doctor in another state (not
licensed to practice in the state where the 'patient' is located)."3
Because the diet pills were so readily available, it is doubtful that the
original physical examination necessary to determine suitability of the drugs
was ever done, and if it was, who was then doing the follow-up physicals re-
quired to watch for side effects." With so little medical supervision, serious
heart and lung conditions were likely to go undetected until it was too late.
C. Medical Implications From Use of Fen-Phen and Redux
Currently, there are two very serious side effects that are being linked to
use of fen-phen and Redux. They are Primary Pulmonary Hypertension
(PPH) and heart valve damage. PPH is characterized by an increased blood
pressure in the blood vessels of the lungs." PPH is a disease of relative re-
cent recognition.4' 'The literature on PPH states that it is fatal in 50% or
more cases, even with attempted treatment." 2 'The linkage of the diet drugs
to PPH has been suggested to tie to the increase of serotonin caused by tak-
ing the diet drugs." 3 The Mayo study of the diet drugs found a high inci-
dence of PPH among those with heart valve problems, "the two side effects
are undoubtedly interrelated in some fashion."
The damage to the heart valves is the appearance of glistening white
valves that are abnormally thickened and as a result, cause regurgitation, al-
lowing blood to flow back into the heart.45 Although a recent study showed
37. See id
38. John Haman, "Fen-phen" Lawsuits Build Momentum, ARK. Bus., Jan. 26, 1998, at 1.
In Arkansas, the number of potential plaintiffs could be extremely large. The reason is that
people from other states would travel to Arkansas to get their diet pills because it was illegal
in their resident state. See id. "We have so many people from Mississippi and in particular,
Tennessee, that came over to Arkansas by the bus load to get their prescriptions," Nibloack,
an Arkansas law firm stated. Id. 'In Tennessee, the board of health wouldn't allow doctors to
prescribe the medication, nor would they allow pharmacies to carry them." Id. "The reason
we have so many potential plaintiffs in eastern Arkansas is that they were running pill mills."
Id.
39. See Rheingold, supra note 6, at 22.
40. See id The term "primary" implies no known cause, so that if the drugs under con-
sideration are found to be causes, the term primary can be replaced with the term secondary.
See id.
41. See id
42. Id Since the earliest signs are non-specific and the doctor may not have alerted the
patient to them, the condition unfortunately may not be detected in its earliest stages, and, in
any case, is said to be hard to diagnose. See id.
43. Id The serotonin constricts the veins, raising the pressure and also making the lungs
more stiff, again creating resistance to air flow. See id.
44. Id.
45. See Rheingold, supra note 6, at 22. "The peculiarities of the valve damage are a
glistening white or wax appearance, plaque-like encasements of the leaflets and chords, with a
'stuck on' appearance." Id. Clinically, there was regurgitation. See id All four valves were
[Vol. 35
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that use of Redux for less than three months is "safe," the study fails to an-
swer the more obvious question of the danger of longer use since it was in-
tended to be a long-term drug. 6
However, the Mayo report concludes that the drugs caused the valve
condition.47 The Mayo Clinic report states that the circulating serotonin is
linked to the damage caused by the drugs, and further states that the drug is
delivered to the right side of the heart first, which is where the PPH and
valve damage has been detected.48 The early signs of disease, as reported
both by the Mayo Clinic and in those who have PPH, are similar: shortness
of breath, especially while exercising, fatigue, and swelling (water retention)
in the lower extremities."
On November 13, 1997, the federal Department of Health and Human
Services (HI-S) recommended medical examinations for anyone who has
taken fenfluramine, the "fen" half of fen-phen combination, or Redux.5° HITS
recommended that all persons who took fen-phen, Pondimin, or Redux see a
physician for a thorough medical checkup with special attention to the heart
and lungs.5 In addition, people with a new heart murmur or heart disease
symptoms such as shortness of breath or swelling in the legs should get an
echocardiogram. 52
Those who will have no choice but to have valve transplants will have
an altered lifestyle forever.53 They generally must stay on blood thinners for
the rest of their lives, plus take other drugs and keep special diets.'
involved in the cases, but the mitral valve was involved more than others. See id.
46. See Daniel Q. Haney, Large Study Exonerates Diet Pill Reduc as Cause of Heart
Valve Damage, Ass. PRESS, Mar. 31, 1998, available in 1998 WL 6648692. The study in-
cluded over 1000 person some of whom were taking Redux, and others that were taking a
placebo. See id. After taking the pill for three months, Redux was recalled and the study
ended. See id Afterwards, each person was given an echocardiogram to make sure there was
no valve damage. See id. The percentage of persons who showed signs of valve damage were
similar for both the Redux group and the placebo group suggesting that Redux is safe. See id.
However, because the study ended when Redux was recalled, the effects of long term use are
still unknown.
47. See Rheingold, supra note 6, at 22.
48. See id. The Mayo Clinic reported having only twice seen similar valve conditions;
those with carcinoid syndrome, which also involves an increase of serotonin, and in those
who take large dosages of ergotanine, a drug that acts similar to serotonin. See id.
49. See id.
50. See id,
51. See Headline: On Call. . . Knight-Ridder, Des Mon_s REG., Feb. 16, 1998, at 3.
52. See id
53. See Rheingold, supra note 6, at 22.
54. See id.
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I. AMCHEM AND ITS EFFECTS ON RECENT LAWSUITS SEEKING CLASS
ACTION CERTIFICATION
A. Federal Rule of Civil Procedure 23 and the Development of Mass Torts
Rule 23 of the Federal Rules of Civil Procedure, governs the require-
ments of certification of class action law suits.s The Advisory Committee
for the 1966 revision of Rule 23 noted that mass accident cases are likely to
present significant questions, not only of damages, but of liability and de-
fenses of liability affecting individuals in different ways.5" The Committee
advised that such cases are ordinarily not appropriate for class treatment.'
The Committee's warning called for caution when individual stakes are high
and disparities among class members great.58
55. Fed. R. Civ. P. 23 (a) and (b) require:
(a) Prerequisites to a Class Action. One or more members of a class may sue or be
sued as representative parties on behalf of all only if (1) the class is so numerous
that joinder of all members is impracticable, (2) there are questions of law or fact
common to the class, (3) the claims or defenses of the representative parties are
typical of the claims or defenses of the class, and (4) the representative parties will
fairly and adequately protect the interests of the class.
(b) Class Actions Maintainable. An action may be maintained as a class action if
prerequisites of subdivision (a) are satisfied, and in addition:
(1) the prosecution of separate action by or against individual members of the class
would create a risk of:
(A) inconsistent or varying adjudications with respect to individual members of
the class which would establish incompatible standards of conduct for the party
opposing the class, or
(B) adjudications with respect to individual members of the class which would as a
practical matter be dispositive of the interests of the other members not parties to
the adjudications or substantially impair or impede their ability to protect their in-
terests; or
(2) the party opposing the class has acted or refused to act on grounds generally
applicable to the class, thereby making appropriate final injunctive relief or corre-
sponding declaratory relief with respect to the class as a whole; or
(3) the court finds that the questions of law or fact common to the members of the
class predominate over any questions affecting only individual members, and that
a class action is superior to other available methods for the fair and efficient adju-
dication of the controversy. The matters pertinent to the findings include: (A) the
interest of members of the class in individually controlling the prosecution or de-
fense of separate actions; (B) the extent and nature of any litigation concerning the
controversy already commenced by or against members of the class; (C) the desir-
ability or undesirability of concentrating the litigation of the claims in the particu-
lar forum; (D) the difficulties likely to be encountered in the management of the
class action.
Id.
56. See Fed. R. Civ. P. 23 advisory committee's note.
57. See id
58. See id
[Vol. 35
8
California Western Law Review, Vol. 35 [1998], No. 1, Art. 5
https://scholarlycommons.law.cwsl.edu/cwlr/vol35/iss1/5
19981 FEN-PHEN CLASS ACTION LAWSUIT IN LIGHT OFAMCHEM
However, when the Advisory Committee suggested changes to the class
action rule in 1966, the phenomenon of mass torts did not exist. Since the
1960s, medical and environmental sciences have become more adept at de-
tecting toxins and links between certain products and injuries.59 As a result,
the mass media have become more willing to cover consumer and safety is-
sues, thereby raising public consciousness regarding potential or alleged
hazards in the environment and in the marketplace.' Moreover, increased le-
gal advertising has brought more potential plaintiffs into the legal system.6
Consequently, tort litigation addressing environmental and product-related
hazards has grown dramatically. With the advent of thousands of seemingly
identical pieces of litigation, the term "mass tort" has emerged and become a
mainstay in legal rhetoric.'
Before a class action is certified, the proposed class has to satisfy Rule
23's requirements. First, a proposed class has to meet the prerequisite re-
quirements of Rule 23(a), then the class has to satisfy Rule 23(b) require-
ments. Of importance for discussion of mass tort class actions is specifically
Rule 23(b)(3), requiring commonality or predominance of factual and legal
issues and Rule 23(a)(4), adequacy of representation among class members.
A class will be able to meet the commonality requirement if the court
finds that the questions of law or fact common to the members of the class
predominate over any questions affecting only individual members.' The
commonality requirement is readily met in certain cases alleging consumer
or securities fraud or violations of the antitrust law." Even mass tort cases
arising from a common cause or disaster may, depending upon the circum-
stances, satisfy the predominance requirement. But it is unclear whether a
mass tort such as the fen-phen/Redux tort will be able to survive the com-
monality test.
The adequacy of representation requirement is met when the needs of
the various members of a class are not in conflict As will be discussed in
further detail later, class members that have suffered a present injury and
those who may suffer in the future are in conflict. The conflict arises because
persons who are presently injured need large immediate pay-outs from any
settlement or verdict. In contrast are persons who may suffer future harm
who need a large inflation-protected settlement fund so that when their in-
jury arises, they will be able to get compensation. Therefore, only if the class
members' needs are not in conflict will the adequacy of representation re-
quirement will be satisfied.
59. See Peter H. Schuck, Mass Torts: An Institutional Evolutionist Perspective, 80
CORNELLL. REv. 941, 946 (1995).
60. See ide at 947.
61. See id
62. See id
63. FED. R. Civ. P. 23(b)(3).
64. See Amchem Products, Inc. v. Windsor, 117 S. Ct. 2231, 2250 (1997).
207
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B. Amchem Products, Inc. v. Windsor
The reason for the confusion as to the fate of the fen-phen/Redux at-
tempts for class certification is the recent Supreme Court case making the
requirements for class certification harder to satisfy. On June 25, 1997, the
Supreme Court held that the requirements for class certification for settle-
ment purposes only had not been satisfied in Amchem Products, Inc. v.
Windsor.65
In Amchem, the settlement class included nine lead plaintiffs designat-
ing themselves and members of their families as representatives of a class
that comprised persons who had been exposed to asbestos either occupation-
ally or through exposure of a spouse or household member.66 The class in-
cluded persons who had manifested physical injuries and persons who had
had not manifested injuries but had been exposed to the asbestos.6
Unlike other proposed class actions that will go to trial, the Amchem
class was seeking certification for settlement only. The Supreme Court had
yet to answer the question of what consideration the fact that the class was
for settlement only would play in the decision of certification. The district
court held that since the class was for settlement, it did not have to meet
Rule 23 requirements." The Third Circuit held that while a class could be
certified for settlement only, it had to meet the requirements of Rule 23, and
did not consider the settlement at all.69 However, the Supreme Court held
that not only must a proposed class meet the Rule 23 requirements, but a
court will also consider the adequacy of the settlement!' The Supreme Court
reasoned that the requirements for certification are designed to protect ab-
sentee class members by blocking unwarranted and/or overbroad class defi-
nitions. Therefore, proposed-settlement class actions demand undiluted, even
heightened attention to the other requirements because the court will lack the
opportunity to adjust the settlement class as it could have done once in-
formed by the proceedings as they unfold.7
In finding that the proposed class did not meet Rule 23's requirements,
the Court first focused on the requirement of commonality, holding that
questions of law or fact did not predominate over questions affecting only
individual members.72 The Court defined the commonality inquiry as focus-
ing "on the legal or factual questions that qualify each class member's case
65. 117 S. Ct. 2231, 2237 (1997).
66. See id at 2239.
67. See id The defendant, Center for Claims Resolution, represented twenty former as-
bestos manufacturers. See id.
68. See Georgine v. Amchem Products, Inc., 157 F.R.D. 246, 315 (E.D. Pa. 1994).
69. See Georgine v. Amichem Products, Inc., 83 F.3d 610, 624 (3d Cir. 1996).
70. See Anchemn 117 S. Ct. at 2248. The requirement of Rule 23(b)(3)(D) that trial
would present intractable management problems is not a consideration for settlement-only
certification because there is to be no trial. See id.
71. See id
72. See id at 2249.
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as a genuine controversy." '73 The Court noted that the commonality require-
ment is not met when there exists a greater number of significant questions
peculiar to the several categories of class members and to individuals within
each category."
The significant questions in Amchem were the means of exposure to dif-
ferent asbestos-containing products, for various lengths of time.7 Other
questions included the resulting disparities in injury and complications of
causation arising from cigarette smoking.76
The commonality question also focuses upon the cohesiveness of the
class as to commonality of remedies, which involves considerations of the
applicable law available to different members of the proposed class, namely
medical monitoring. The proposed class action sought to achieve global set-
tlement of current and future asbestos-related claims.' The fact that all
members had been exposed to asbestos products was insufficient to meet the
predominance standard because different members were exposed to different
products for different amounts of time in different ways and the differences
in state law compounded those issues.
Besides finding that the proposed class did not satisfy the commonality
requirement, the court also held that the proposed class did not satisfy the
adequacy of representation requirement.8 In finding that the requirement
was not met, the Court held that the named parties did not fairly and ade-
quately protect the interests of the class because the named parties sought to
act on behalf of a single giant class rather than on behalf of discrete sub-
classes." The goal of class members who were currently injured and needed
immediate payment conflicted with the interests of exposure-only plaintiffs
in ensuring an ample, inflation-protected fund for the future. Further, the
proposed settlement had no structural assurance of fair and adequate repre-
sentation for diverse groups and individuals affected.8'
C. Proposed Class Action Lawsuits after Amchem
Since the Supreme Court's decision in Amchem, there have been three
noteworthy cases seeking class certification in the area of mass torts. Each of
those cases focused on either the commonality requirement or the adequacy
of representation requirement. Only one of the three was able to satisfy both
requirements and be certified as a class action.
73. Id
74. See id. at 2250.
75. See id
76. See id
77. See id at 2245.
78. See id at 2250.
79. Seeid at2251.
80. See id
81. See id
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The first case since Amchem to deal with the questions of commonality
and representation was Walker v. Liggett Group, Inc.12 decided on August 5,
1997. The proposed class had received preliminary approval of a mandatory
settlement class brought against cigarette manufacturers."
The proposed class consisted of all past and present smokers of ciga-
rettes or users of tobacco products manufactured by Liggett who reside in
the United States and who claim to have suffered injury as a consequence
thereof."
The proposed class in Liggett is even more expansive than the proposed
class in Amchem. The Liggett court was concerned with the proposed class
because the complaint only named one plaintiff as representative to the class
that could number in the millions." The named plaintiff suffers from serious
cancers allegedly caused by the Liggett products."
In comparison, the proposed class sought to encompass not only smokers
whose prolonged habits led to their current injury, but presumably any one
of the following as well: 1) those picking up a Liggett-manufactured ciga-
rette for the first time today, who may have manifestations 10 years, 20
years, or never; 2) those who have smoked Liggett brand with varying
levels of nicotine and carcinogens; 3) those who smoked cigarettes but
who also might have independent competing causal factors such as expo-
sure to work-related chemicals; 4) those who do not have cancer now but
may have it or a number of other smoking related injuries; 5) those who
have been exposed to second hand smoke; 6) and a number of others
whose exposure varies widely from the named representative. '
The court denied certification because the various combinations of sub-
classes within this "gargantuan" assembly of plaintiffs would appear to defy
definition, much less division. While the plaintiffs also sought certification
for medical monitoring, West Virginia does not recognize a cause of action
for medical monitoring.
82. 175 F.R.D. 226 (S.D.W. Va. 1997).
83. See Walker, 175 F.R.D. at 227.
84. See id at 226. The group also included the estates of smokers, spouses, children,
relatives, and significant others as their heirs or survivors, and all persons in the United States
who have been, or claim to have been, exposed to environmental or second-hand smoke and
have suffered an injury. See id. The group goes on to include all persons in the United States
who have incurred losses as a result of paying for or providing treatment for diseases, ill-
nesses, or medical conditions of the persons defined above allegedly caused by tobacco prod-
ucts. See id. Finally, all persons in the United States who have either smoked or used tobacco
products, or have been exposed by way of environmental or second hand smoke, and claiming
to have suffered injury as a consequence thereof and in connection with such a claim, allege
that the defendants engaged in a fraud, conspiracy, or concerted activity with one or more
other tobacco product manufacturers in the manufacturing, sale, or marketing of tobacco
products. See id.
85. See id at 332.
86. See id
87. Id
88. Id at 232.
89. See id at 227. See also supra note 83 and accompanying text.
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The court also held that the adequacy of representation requirement for
certification of a class action was not met2" The court held that the "bedrock
consideration for the court in any certification is whether a proposed class
has sufficient unity so that absent members can fairly be bound by decisions
of class representatives."'" As stated in Rule 23(a)(4) "the representative
parties will fairly and adequately protect the interests of the class."9 One
necessary element in this requirement is whether there are conflicts of inter-
est between named parties and the class members they seek to represent.93
The Supreme Court in Amchem was concerned about the conflicting in-
terests between plaintiffs who were currently injured, needing generous im-
mediate payments, and the exposure-only plaintiffs needing an ample infla-
tion-protected fund for the future.94 Likewise, the Liggett court held that the
conflicting interests did not satisfy the requirement of fair and adequate rep-
resentation of the class.95
The second case involving a mass tort injury, decided on August 28,
1997, was In re Ford Motor Co. Ignition Switch Products Liability Litiga-
tion 6 Again, the court focused on the requirements of commonality and
found that they had not been met.
The case contained two different classes. The first class comprised
plaintiffs seeking certification of an action brought on behalf of purchasers
and lessees whose vehicles had caught fire as a result of a defective ignition
switch.97 The second class was a nationwide consolidation of cases from
various courts each involving plaintiffs owning a Ford automobile with the
defective switch.9' However, in the second class, there were no allegations
that the class members' vehicles had caught fire as a result of the ignition
switch, and therefore, they had not sustained smoke or fire damage in their
vehicles.99
In rejecting the proposed classes, the court held that common factual is-
sues did not predominate because the questions of defect likely may have
turned on facts particular to each plaintiff or at the very least, assessments of
risk for each of the 158 models at issue.' The court also considered the dif-
ferences in state law as precluding satisfaction of the commonality require-
ment.'' For example, in order to prove an implied warranty claim in some
90. See id
91. ld (quoting Amchen, 117 S. Ct. at 2248).
92. FED. R. Civ. P. 23(a)(4), cited in Walker, 175 F.R.D. at 230.
93. I. at 231 (quoting Amchem, 117 S. Ct. at 2248).
94. See Amchem, 117 S. Ct. at 2250.
95. See Walker, 175 F.RD. at 227.
96. 174 F.R.D. 332 (D.N.J. 1997).
97. See id. at 336.
98. See id
99. See id at 337. Similar to a cause of action for future damages in that they have been
exposed to a danger and may need compensation in the future.
100. See FordMotor Co., 174 F.R.D. at 341.
101. See id at 346.
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states, the plaintiff must demonstrate contractual privity with the defen-
dant." Plaintiffs from these states will have to prove that they purchased
their Ford vehicle either from Ford itself or one of its agents as opposed to
an independent car dealer or another individual. 3 This would require the
court to under take an inquiry that will turn on facts particular to each indi-
vidual. Because both cases failed to satisfy the predominance requirement,
the court concluded that certification would not be appropriate.'
The third mass tort case decided on October 17, 1997, is In re Orthope-
dic Bone Screw Products Liability Litigation.' Unlike the two previous
cases, this case was given class certification for settlement purposes."0 6 In
certifying the proposed class for settlement, the court went through each of
Rule 23's requirements, specifically the commonality and adequacy of rep-
resentation requirements, and held that each had been met.
The settlement class consisted of all orthopedic bone screw recipients in
whom an orthopedic bone screw was implanted on or before December 31,
1996, who have or may have claims against Acromed.'" Spinal fusion sur-
gery involving orthopedic bone screw implants is a substantial medical pro-
cedure.' 1 Individuals who have undergone this substantial procedure know
that the surgery has occurred.' Exposure to spinal fusion surgery is, there-
fore, unlike exposure to hazardous substances, where persons may not learn
of their exposure until years after it occurred."0 The court also received
medical evidence that "the consequences of a failed spinal fusion surgery, no
reduction in preoperative pain and no improvements in preoperative function
or mobility, virtually always become apparent within four months or less
after surgery."'
The court first focused on what consideration was to be given to the fact
that the class was for settlement only. The court applied the rule from
Amchem that while a proposed settlement may be considered as a factor, it
may not be a substitute for any of Rule 23's requirements."2
The court must first find that questions of law or fact common to the
members of the class predominate over any questions affecting only individ-
ual members."3 First, the Orthopedic Bone Screw settlement class is not
102. See id
103. See id.
104. Seeid, at351.
105. 176 F.R.D. 158 (E.D. Pa. 1997).
106. See id at 165. The problem with the bone screws was first made public in Decem-
ber 1993 on the ABC News program 20/20 that featured the screws. After the broadcast,
thousands of people filed suit against Acromed, the manufacturer. See id.
107. See id at 173.
108. See id
109. See id
110. See id
111. l
112. See id at 172.
113. See FD. R. Civ. P. 23(b)(3).
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sprawling like the Amchem class. The class here is much more defined and
congruous."' Second, there is no "futures" problem like the one present in
Amchem because all persons who had the surgery done with the defective
screw will know they are injured within four months."' A common question
of fact or law is one that arises from a common nucleus of operative facts." 6
The common questions of law and fact in the bone screw case are on the is-
sue of whether the orthopedic bone screws are defective products that are
unreasonably dangerous."'
Rule 23(a)'s adequacy of representation requires that the representative
parties fairly and adequately protect the interests of the class."' The question
of adequacy of representation has two components designed to ensure that
absentee class members' interests are fully pursued."9 First, "the interests of
the named plaintiffs must be sufficiently aligned with those of the absen-
tees."'' This component includes an inquiry into conflicts among various
class members. The named class members must have the ability and incen-
tive to vigorously represent the claims of the class as well as their own
claims.' Second, class counsel must be qualified and must advance the in-
terests of the entire class not just the named members."
In Orthopedic Bone Screws all the members of the class were interested
in seeking equitable relief and maximizing the size of the settlement fund."
The court declined to create subclasses because there were no great diver-
gent conflicts. 24 Further, the claims of individuals implanted with orthopedic
bone screws on or after January 1, 1997, were not included in the settlement
class." The settlement fund will not be disturbed or affected by those claims
and the settlement does not bar any such claims.2 6 Therefore, as discussed
above, there is no "futures" conflict in this class like the one in Amchem be-
cause the court found that the representative plaintiffs did not have interests
antagonistic to those of the absent class members."z
114. See Orthopedic Bone Screw, 176 F.R.D. at 173.
115. See id
116. See id. at 174.
117. See id
118. See Amchen 117 S. Ct. at 2250.
119. See Orthopedic Bone Screw, 176 F.R.D. at 175.
120. lId
121. See id
122. See id at 176.
123. See id
124. See ie
125. See id
126. See ide
127. See id.
15
Vanderslice: Viability of a Nationwide Fen-Phen/Redux Class Action Lawsuit in
Published by CWSL Scholarly Commons, 1998
214 CALIFORNIA WESTERN LAW REVIEW [Vol. 35
IV. DIFFERENT APPROACHES TO RESOLVING THE FEN-PHEN/REDUX
LITIGATION AND THE LIKELIHOOD OF CLASS ACTION CERTIFICATION
A. The Current Status of Class Action Certification
In September of 1997, plaintiffs' lawyers litigating over the diet drugs
fen-phen and Redux filed an application with the Judicial Panel on Multi
District Litigation (JPMDL) in Washington seeking to consolidate the suits
for pretrial proceedings."' In December, the JPMDL ordered the consolida-
tion."9 The effect of this order will be that all lawsuits currently filed and any
future lawsuits fied in federal court will be handled by U.S. District Judge
Louis Bechtle 30 Bechtle will coordinate all pretrial hearings and lawyers on
both sides will use depositions and other evidence gathered in the proceed-
ings." In February of 1998, Bechtle selected nine nationally known litiga-
tors to form a committee that will coordinate all of the pretrial stages of the
litigation."' In May of 1998, Bechtle appointed defense liaison counsel for
retailers, diet centers, and physicians in the multi-district litigation.33 As dis-
covery continues to unfold, battles over on-going medical studies continue
with hopes of beginning depositions in the fall."
128. See Joanne Wojcik, 1997 Risk Management: Courts, Plaintiffs Lash Out at Mass
Tort Settlements, Bus. INs., Dec. 22, 1997, at 16. At the time there were just seven cases, ac-
cording to papers filed with the panel. See id. But the plaintiffs promised more cases would
follow. See id. By December 1997, lawyers for AHP and Internueron reported to the panel
that they had already been sued in nearly 300 cases throughout the country, 200 of which are
in federal court. See id. Thirty of the federal cases seek certification of nationwide classes; 70
are content to limit themselves to statewide classes. See id.
129. See Philadelphia Federal Court to Handle Diet Drug MDL: Judge Bechtel to Over-
see, MEALY's LrrIG. R'r.: DRUGS AND MEDICAL DEv'cns, Dec. 19, 1997, at 11. The JPMDL
decided that locating the diet drug MDL in the Eastern District of Pennsylvania "will serve
convenience of the parties and witnesses and promote the just and efficient conduct of this
litigation." Id. Because of more than 200 individual and nationwide or statewide class actions,
"centralization under section 1407 is thus necessary in order to eliminate duplicative discov-
ery, prevent inconsistent or repetitive pretrial rulings (especially with respect to class certifi-
cation), and conserve the resources of the parties, their counsel and the judiciary," the panel
said in its order. Id.
130. See InBrief, LAS VEGAS REviEw-JOURNAL, Dec. 13, 1997, at 1D.
131. See Philadelphia Federal Court, supra note 129, at 11.
132. See Richard B. Schmitt, Judge Names Nine Lawyers as Members of Steering Com-
mittee in Diet-Pill Case, WALL ST. J., Feb. 6, 1998, at B2. The lawyers include Stanley
Chesley, of Cincinnati, Arnold Levin of Philadelphia, John Cummings of New Orleans, Di-
anne Nast of Lancaster, Will Kemp of Las Vegas, Darryl Tschirn of La Jolla, Michael Haus-
feld of Washington D.C., Roger Brosnahan of Minneapolis and Elizabeth Cabraser of San
Francisco. See id Under an order issued by Judge Bechtle, the lawyers said they expect to
move quickly, hopefully launching pretrial fact finding, such as the taking of depositions, in a
month or two at most. See id. In addition, the judge ordered the lawyers to develop a detailed
list of plaintiffs in the case, including information about their alleged injuries, in an effort to
gauge the scope of the proceeding. See id.
133. See MDL Defense Liason Counsel Designated for Retailers, Physicians, Diet Cen-
ters, MEALEY's LING. REP.: FEN-PHEN/REDux, May 1998, at 8.
134. See Fen-Phen Plaintiffs Seek Ongoing Study; Scientific Privilege Cited, MEALY's
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Most important to the discussion of class action is that Bechtle will be
the judge that will ultimately determine whether any of the proposed class
actions will be certified."' However, once the cases have completed pretrial
proceedings, including determinations of class action certification, they will
be returned to the federal courts in which they were originally filed."'
B. Individual Lawsuits versus Class Action Lawsuits
Perhaps one of the more contested aspects of the fen-phen/Redux litiga-
tion is whether to pursue individual lawsuits or class action lawsuits."7 Both
approaches have their supporters among plaintiffs' lawyers. But the consid-
erations of which to pursue go far beyond having to satisfy Rule 23's re-
quirements. At the heart of the debate are the equitable considerations of
plaintiffs' needs: 1) the need for swift resolution of their claim, that is better
resolved by individual suits; and 2) the need to represent potentially millions
of plaintiffs with common claims, that is best resolved by class actions.'
The issues presented by the Amchem settlement are of interest to all
lawyers struggling with the question of individual rights and aggregate jus-
tice. 39 The fundamental question is whether the traditional models of adjudi-
cation and due process, designed to protect the individual rights of litigants,
can be expanded to meet the needs posed by mass product liability involving
hundreds or thousands of cases.14 Plaintiffs' lawyers like Paul Rheingold,
head of American Trial Lawyers Association's section on diet pill litigation,
prefer the case-by-case approach, which he says is not only faster than a
class action but more equitable. In his opinion, the biggest problem with
class action lawsuits is attorneys who accept clients solely to enhance the
power of the class action lawsuit. 4 ' In the end, this benefits lawyers with
large attorney fees for cases that were too weak to survive on their own.'42 In
addition, by rewarding class action lawsuits with large settlements, the in-
evitable result will be to reduce the compensation available to plaintiffs with
serious medical needs such as heart valve or lung transplants. 4' In other
LrrIG. RPr.: DR Gs AND MEDICAL DEvIc s, May 22, 1998, at 21; Zina Moukheiber, Man-
agement, Strategies, Trends, FORBES, July 6, 1998, at 176.
135. See Schmitt, supra note 132, at B2.
136. See Lexecon, Inc. v. Milberg Weiss Bershad Hynes & Lerach, 523 U.S. 26 (1998).
The Court held that a district court conducting the pretrial proceedings cannot transfer the
case to itself for trial. See id.
137. See Hansen, supra note 9, at 24.
138. See id
139. See Eric D. Green, Advancing Individual Rights Through Group Justice, 30 U.C.
DAVIS L. REv. 791 (1997).
140. See id
141. See Hansen, supra note 9, at 24.
142. See Sheila R. McCann, The Jury is Still Out on Class Action Lawsuits Option
Serves Plaintiffs Well, Some Say; Others Claim the Only Winners Are the Lawyers; Class Ac-
tions are On Trial SALT LAKE TRm., Mar. 22, 1998, at Al.
143. See Hansen, supra note 9, at 24.
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words, adjudication and due process do not appear to be unlimited resources;
supplying all resources to one class action may inevitably deprive others of
their share.
The potential outcomes reflect the natural progression of a relatively
new phenomenon-mass tort litigation from a collection of individual
cases to a consolidated or class-wide case subsuming thousands of parties."M
In mass tort class actions, because of the numerosity requirement, one must
be concerned simultaneously with the rights of thousands of individuals.45
"Given the nature of our legal system, some of these individuals are going to
be at the end of a very long line, figuratively shouting up the line 'turn on
the due process' only to hear echoing back, 'sorry, you'll have to wait ten
years,' or worse, 'sorry, it's all run out."" 6 Because class actions involve
thousands of plaintiffs, most of whom are not known, it is hard to accurately
formulate a result. The potential for a settlement fund to run out of money
before meeting the needs of all persons injured by fen-phen or Redux is
great. The one way to avoid the problem of an insufficient fund is to have
individual lawsuits where each claim is assessed for its own merit and com-
pensated accordingly.
However, some of the values furthered by class actions, access, eco-
nomic efficiency, flexibility and economic optimality, and elimination of
risk, cannot be achieved by individual lawsuits. 47
The primary virtue of class actions is that they provide a mechanism for
access to thousands of people who might not otherwise be represented or
have any realistic chance of getting their case heard.'4' Many former users of
fen-phen and Redux need to have an echocardiogram to ascertain the health
of their heart but unfortunately, many of those persons cannot afford the cost
of test. Their only hope is to join a class action lawsuit that will try to force
the diet pill manufacturers and other defendants to pay for the procedure.
149
Thus, without the class action, it is unlikely that their individual case would
ever be heard because it would be too expensive for each person to litigate
compared to the approximately $1,000 cost of an echocardiogram.'50
The second benefit is economic efficiency, both in resources and in
time.' Class actions can be an incredibly powerful tool by allowing individ-
ual victims to come together to fight a larger, stronger, more well-armed de-
fendant. For plaintiffs' lawyer Bill Marler, who filed a class action lawsuit
for victims of E. coli infected hamburgers from Jack in the Box, class ac-
144. See Green, supra note 139, at 791.
145. See id. at 798.
146. Id at 799.
147. See id. at 801.
148. See id
149. See McCann, supra note 142, at Al.
150. See infra note 159 and accompanying text.
151. See Green, supra note 139, at 801.
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tions level the playing field.1 2 Plaintiffs' lawyer Wendell Gauthier, who filed
the first national class action lawsuit against the tobacco industry in 1994,
says that he was able to discuss settlement only because of the power of
class action lawsuits; before class actions, the tobacco industry was able to
use all of their economic resources to defeat every individual lawsuit. 53
The third benefit is flexibility and economic optimality in shaping the
remedy, allowing for the types of remedies that are needed in many of these
situations. For example, different types of pay-outs for different types of
proof, taking into account the fact that some people have certain kinds of
proof and other people do not. 54
Finally, a major benefit of settlement classes is elimination of risk. 5
Without a known limit on liability, there is a risk that defendants could go
bankrupt paying litigation fees for individual cases and some plaintiffs
would never recover.
Weighing both of these considerations, it seems that class action law-
suits are most effective for the small financial claims such as consumer
fraud, for which the rule was originally intended.56 Within that framework,
claims for medical testing and monitoring would be best resolved in the class
action arena. 57 In contrast, claims for serious injuries, such as valve trans-
plants or even wrongful death claims, are better left to individual lawsuits
because individualized justice will ensure full compensation as opposed to
merely being part of some monstrous class action.
C. Satisfying the Requirements of Class Action Certification
Of the complaints alleging a class action in federal court, there are two
predominate themes; one class action seeks costs of medical monitoring and
the other seeks damages for serious present and future injuries.'5 While the
two different class actions seek different remedies, both will still have to
meet the requirements of Rule 23 as interpreted in Amchem. Of significance
are the requirements of adequacy of representation and commonality of the
class. 15
9
152. See McCann, supra note 142, at Al.
153. See id
154. See Green, supra note 139, at 801-02.
155. See id at 802.
156. See FED. R. Civ. P. 23 advisory committee's note.
157. See McCann, supra note 142, at Al.
158. See Fen-PhenRedu, MEALEY'S LITIG. Rrr., Sept. 1997, at D-1. Class actions for
medical monitoring seek compensation for the cost of medical examinations both past and
future for all users of the diet drugs and also medical tests including the expensive echocar-
diogram test that can cost upwards of $1,000. See id. Class actions for serious injuries seek to
represent persons in the United States and U.S. territories who have suffered or may suffer
injury from fenfluramine, phentermine and dexfenfluramine. See id. Injuries include persons
who have developed or will develop PPH, valvular disorder, or other serious injury. See id.
159. See discussion, supra Part M.
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To succeed in getting a class action certified, the requirement of ade-
quacy of representation first has to be satisfied. After considering Amchem
and the cases that have subsequently been decided, it seems that present and
future injuries cannot be maintained in the same class. The conflicts between
recovery for immediate harm and recovery for possible future harm are in
conflict. They are in conflict because plaintiffs with present injuries will
want full compensation immediately for their injury. Plaintiffs seeking future
damages want there to be a limited pay-out now to ensure that if they de-
velop valvular disease or PPH there will be enough money in the fund to
award full compensation of their injury. Of the cases discussed supra Part
I, two were denied class certification and the only one that was granted
class certification was the class without damages for future plaintiffs. There-
fore, it seems the one clear lesson learned from Amchem is that in order to
satisfy the adequacy of representation requirement, class actions for future
injuries cannot be combined with class actions for present injuries to form
one huge class.
However, some class action lawsuits that have been filed in federal
courts seeking certification have not followed this conclusion.16 Instead,
they are seeking to represent both present and future victims of the diet
drugs in a "serious injury class. 16 Although the court has made no determi-
nation on certification of any class actions, it seems unlikely that the serious
injury class will win certification because of the conflict in representing
class members whose compensation needs are at odds with each other.
Although the solution to this problem would seem to be simply dividing
the two classes, one for present injury and one for future injury, the sub-
classes will still likely not succeed in their attempts at certification for failure
to meet the second requirement of commonality discussed below.
Distinct from present and future serious injury class actions are medical
monitoring class actions."' Unlike the serious injury class, the medical
monitoring classes do not have the same representation conflicts as the seri-
ous injury classes. The reason is that the medical monitoring class actions
are seeking damages that will have a known pay-out now and in the future,
namely medical examinations and echocardiograms." In contrast, the seri-
ous injury class does not have a known pay-out as it is impossible to ascer-
tain who and to what degree class members will be injured now and in the
160. See Fen-Phen/Redux, supra note 158, at D-1.
161. I
162. See id. The first class action was filed in San Francisco with a claim that the manu-
facturers of fenfluramine and phentermine failed to adequately warn that the FDA had not
approved concomitant use of the drugs, plaintiffs contend in a class action filed July 9, 1997.
See id. The complaint lists counts for strict product liability pursuant to Restatement (Second)
of Torts Section 402A (1965), failure to warn, negligence, and breach of express and implied
warranty. See id.
163. See Class Action Complaint Filed Against Makers of Fen-Phen Diet Drugs,
MEALY'S LrIG. RPr.: DRUGs AND MEDICAL DEVcES, July 18, 1997, at 8.
[V/ol. 35
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future."6 As a result of the different remedy sought in the medical monitor-
ing class, there is no conflict between plaintiffs trying to collect now and in
the future for undetermined'amounts and the requirement of adequate repre-
sentation will likely be satisfied.
As mentioned previously, even if the adequacy of representation re-
quirement is satisfied by dividing the present and future injury classes, the
classes will have a difficult time overcoming the commonality requirement
because there are many issues as to causation and possible defenses. 65 In
both class actions (medical monitoring and serious injuries), the defendants
include the diet pill manufacturers, distributors, doctors and diet centers that
gave away or prescribed the diet pills.1' The likely defenses that each one
will assert will depend on whether the class action is seeking damages purely
because they were exposed to the diet drugs (medical monitoring) or dam-
ages for injuries that have or have not yet manifested in the form of heart
valve damage or PPH. The success of the class action certification will likely
turn on whether the class action is seeking damages for medical monitoring
or damages for present and future serious injury.
The advantages of class actions that are seeking medical monitoring
costs over class actions that are seeking damages for serious injuries are sig-
nificant. The strategy of pursuing medical monitoring costs avoids many
causation and damages issues peculiar to individual plaintiffs."6 In the medi-
cal monitoring class, all class members used either fenfluramine ("fen") or
dexfenfluramine ("Redux"), and are seeking medical expenses related to the
exposure of the diet drugs. Any defenses that would consider the individual
plaintiffs' medical history would be irrelevant because they are seeking
damages for testing and not compensation for manifested injuries. Further,
as mentioned previously, the HHS advised fenfluramine and dexfenflura-
mine users to take precautionary steps by getting a medical exam, which
might include an echocardiogram. The pronouncement by HIIS does not
distinguish the need for medical monitoring based upon individualized case
histories, circumstances of usage, or whether the drugs were used in combi-
nation with other drugs, such as phentermine ("phen")."65 Unfortunately,
there is one serious drawback to the medical monitoring class action. The
164. See id. Plaintiffs seek to represent persons nationwide who have taken fenfluramine,
phentermine, and dexfenfluramine, either individually or in combination. See id. The pur-
ported class seeks a medical monitoring program to monitor alleged dangerous side effects,
including PPH and valvular heart disease. See id. The complaint states that defendants en-
couraged the combination use of the drugs in order to increase sales. See id. Plaintiffs contend
that the drug makers undertook an "advertising blitz" to create widespread use of the drugs.
See id. Also, plaintiffs assert that the manufacturers understated health hazards and risks asso-
ciated with use of the drugs. See id.
165. See Fen-Phen/Redux, supra note 158, at D-1.
166. See id.
167. See Van Voris, supra note 7, at Al.
168. See Medical Monitoring Class Certification Sought in New Jersey, MEALY's LTIG.
RPT.: FEN-PHEN/REDux, June 22, 1998, at 12.
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drawback is that the cause of action for medical monitoring is not recognized
in certain jurisdictions. 69 As a result, plaintiffs in some jurisdictions will not
be able to be a part of the class and will be left to pursue alternate means of
compensation.17
While the medical monitoring cause of action will likely be able to sat-
isfy the commonality requirement, it is doubtful that the serious injury class
will also. For the serious injury class, there are too many questions as to cau-
sation and defenses. For example, age is a relevant factor in determining the
possible causes of valvular damage.1 A person of advanced age may have
had a rheumatic disease due to infection earlier in their life that could mani-
fest itself now as valve damage. 72
Another consideration is the severity of the injury. Valvular disease can
range from minor to severe damage. Some doctors have suggested that once
you have valvular disease, the damage will continue to become more severe
even if you stop taking the diet drugs.'" Therefore, once you show signs of
minor valve damage you can be sure that it will become more severe. How-
ever, that statement does not reflect reality. In a study of over 1,000 persons,
some using the diet drugs and others not, both groups had almost the same
percentage of persons with minor valvular disorder." The study merely
shows what experts already knew-that minor valve disorder can be found
with sophisticated diagnostic machines in almost everyone.75 The implica-
tion is that persons with minor valvular disorder may develop a serious in-
jury resulting in a valve transplant or the minor valve disorder could remain
minor because it is not caused by the diet drugs but is rather a common oc-
currence in most people. Although the solution to this problem would be to
include only persons who have severe heart damage, that solution is also
flawed. The severe valvular disease may have been caused by something in
their childhood.
Therefore, having a class action for persons with serious injuries does
not meet the common questions of causation because not all valvular disor-
ders will lead to severe damage and not all severe valve damage is caused by
fen-phen or Redux. With these differences, it seems unlikely that plaintiffs'
169. See Van Voris, supra note 7, at Al.
170. See id. Alternative means of compensation include filing individual lawsuits or
joining a different class action hoping to recover costs that have already been paid out. See id.
The obvious problems with this choice are that diet drug users may not have the economic
resources to front the medical costs for an indefinite period of time. See id. In addition, plain-
tiffs will have a hard time getting their case to trial because the dollar amount is so low. See
id.
171. See Guy P. Curtis, Lecture on fen-phen at Thorsnes, Bartolotta, McGuire & Padilla
(Feb. 23, 1998). Dr. Curtis is the Director of Cardiac Electrophysiology at the Scripps Clinic
in La Jolla, CA.
172. See id
173. See CBS This Morning, supra note 1.
174. See Haney, supra note 46.
175. See id.
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lawyers will be able to tailor a class of plaintiffs that can overcome the
problems of causation. The end result is, of course, that the class will not
meet the requirement of commonality.
In addition to problems of causation, the serious injury class will also
have problems with various defenses asserted by some of the defendants.
Possible problems include which defendants had knowledge of the potential
health hazards. While ABP and Interneuron may have known of the health
hazards because of similar reports in Europe, it is not likely that the diet
centers or doctors knew of those cases.
Other possible problems that involve individual issues include pre-
scribing fen-phen/Redux to persons who were not obese, prolonged use,
overdosing, failure to or inappropriate monitoring, prescribing off label, and
lack of informed consent. Redux was approved for use by persons whose
BMI number was thirty or above. However, in many cases, persons whose
BMI number was significantly lower than thirty were still prescribed Re-
dux.76 Therefore, defendants will argue that since not all purported class
members should have been prescribed the diet drugs, individual questions as
to BMI numbers of each plaintiff will predominate the lawsuit Similar to the
problems with individual class members' BMI number, individual questions
as to how long plaintiffs were prescribed the diet drugs and in what dose will
predominate the lawsuit.77 Another issue is how quickly the plaintiffs were
first diagnosed with medical problems. The physicians had a duty to monitor
and do periodic examinations on all persons who were prescribed the diet
pills. Individual issues remain as to which doctors competently monitored, or
even monitored at all, their patients health and whether they should have
been able to detect heart murmurs in a timely manner.
Finally, the diet pill manufacturers will to assert that it was the doctors'
responsibility to adequately warn the patients and it was the doctors, not the
manufacturers, who prescribed the diet pills to persons who were not clini-
cally obese. In addition, most of the plaintiffs in the purported class will
have had different doctors. The defendant doctors will likely have their case
severed from the class action, requiring them to be pursued on an individual
basis if at all. What is left for the class action is the fact that each doctor may
have informed their patients to varying degrees, some may have had no in-
176. See Paul J. Napoli, Physician Liability in Diet Drug Litigation, N.Y.L.J., Apr. 20,
1998, at 1. The reason the BMI number is significant is that the rationalization for approving
Redux was balancing the health risks of obesity with the health risks of Redux. See id. The
FDA decided that the risks of obesity far outweighed any possible side effects of Redux. See
id. However, for persons who were not obese and needed to loose only ten or fifteen pounds,
the risks were not outweighed. See id.
177. See id. Fenfluramine and phentermine were approved for use on a short-term basis,
i.e., over a few weeks. See id. The reason was that after a few weeks, the person would start to
develop a tolerance for the diet drugs and their effectiveness would be gone. See id. Instead of
discontinuing the use, physicians were continuing to prescribe the diet drugs in either the
same dosage (which was futile) or would increase the dosage thereby making the injury to
plaintiff that much worse. See id.
23
Vanderslice: Viability of a Nationwide Fen-Phen/Redux Class Action Lawsuit in
Published by CWSL Scholarly Commons, 1998
CALIFORNIA WESTERN LAW REVIEW
formation while others may have had full disclosure. By having various de-
fenses by various defendants, the requirements of commonality, especially
common questions of law and fact, are not present within this class. What is
present are lingering questions that are tailored to the individual plaintiff or
defendant and are not common among the entire class.
V. CONCLUSION
After considering both the causation issues and various defenses of
knowledge and disclosure, it does not seem likely that a class for serious in-
juries will be certified. Even if the class was divided into present and future
injuries in order to overcome the representation requirement, the classes
would still fail to meet the commonality requirement. Too many questions
regarding the individual plaintiffs' severity of injury and cause of injury, as
well as different defenses available to the defendants, ends up resembling
less of a unified common class and more of a group of individual cases.
Consequently, it is probable that the only class action lawsuits that will be
certified are those seeking medical monitoring, provided that the respective
jurisdiction allows it. Moreover, the serious injury class, whether present or
future, will not meet the rigid requirements of Rule 23 as interpreted in
Amchem because there is neither adequate representation nor commonality
among the class members.
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